Today: January 23, 2019, 9:11 am
  
Business

Spark Therapeutics to Host Conference Call on Tuesday, Feb. 20 at 8:30 a.m. ET to Discuss 2017 Results and Recent Business Highlights

PR-Inside.com: 2018-02-13 13:33:01

Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a conference call on Tuesday, Feb. 20, 2018, at 8:30 a.m. ET to discuss corporate and financial results for the year that ended Dec. 31, 2017 and recent business highlights.

The call can be accessed by dialing (855) 851-4526 (domestic) or (720) 634-2901 (international), and entering passcode 9596288. To access a live audio webcast, please visit the "Investors" section at www.sparktx.com.

A replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international), and entering passcode 9596288, or by visiting the "Investors" section at www.sparktx.com.

About Spark Therapeutics
At Spark Therapeutics, a fully integrated company committed to discovering, developing and delivering gene therapies, we challenge the inevitability of genetic diseases, including blindness, hemophilia and neurodegenerative diseases. We have successfully applied our technology in the first FDA-approved gene therapy in the U.S. for a genetic disease, and currently have three programs in clinical trials, including product candidates that have shown promising early results in patients with hemophilia. At Spark, we see the path to a world where no life is limited by genetic disease. For more information, visit www.sparktx.com, and follow us on Twitter and LinkedIn.

Investor Contact:
Ryan Asay
Ryan.asay@sparktx.com
(215) 239-6424
Media Contact:
Monique da Silva
Monique.dasilva@sparktx.com
(215) 282-7470



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Spark Therapeutics, Inc. via Globenewswire




# 499 Words
Related Articles
 
More From Business
Sanli has secured S$51.5 million worth of [..]
SINGAPORE, Jan 22, 2019 - (ACN Newswire) - Sanli Environmental Limited ("Sanli" and together with its subsidiaries, the [..]
3,300+ Finance, Business Leaders Join Asian Financial [..]
HONG KONG, Jan 16, 2019 - (ACN Newswire) - More than 3,300 financial policymakers, financial elites and business leaders attended [..]
The Executive Talk: Chememan PCL (SET:CMAN)
BANGKOK, Jan 15, 2019 - (ACN Newswire) - Chememan PCL (SET:CMAN) Chief Executive Officer, Mr. Adisak Lowjun discusses the company's [..]
Sapphire's Subsidiary Awarded EPC Contract of RMB [..]
SINGAPORE, Jan 15, 2019 - (ACN Newswire) - SGX Mainboard-listed Sapphire Corporation Limited ("Sapphire", and together [..]
Hong Kong Investment Promotion chief visits London [..]
HONG KONG, Jan 14, 2019 - (ACN Newswire) - The Director-General of Investment Promotion of the Hong Kong Special Administrative [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.